Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
Thrombocytopenic Purpura
About this trial
This is an interventional treatment trial for Thrombocytopenic Purpura focused on measuring Immune Thrombocytopenic Purpura, Idiopathic Thrombocytopenic Purpura, ITP, Thrombocytopenia
Eligibility Criteria
Inclusion Criteria: Greater than or equal to 3 months history of ITP, regardless of splenectomy status, and completion of at least 1 prior treatment for ITP 2 of 3 pretreatment platelet counts that were less than 30 x 10^9/L (if not currently on ITP therapy) or less than 50 x 10^9/L (if currently receiving corticosteroids for ITP therapy) Ability to give informed consent Exclusion Criteria: Known history of arterial thrombosis, active malignancy, or bone marrow stem cell disorder
Sites / Locations
Arms of the Study
Arm 1
Experimental
Romiplostim
Participants will receive a maximum of 2 administrations of romiplostim by subcutaneous injection, the first on day 1 of the study and the second on day 15 or 22 depending on the participant's platelet count. Romiplostim doses to be tested were 30, 100, 300, and 500 μg.